Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma.
Xu-Monette, Zijun Y; Deng, Qipan; Manyam, Ganiraju C; Tzankov, Alexander; Li, Ling; Xia, Yi; Wang, Xiao-Xiao; Zou, Dehui; Visco, Carlo; Dybkær, Karen; Li, Jun; Zhang, Li; Liang, Han; Montes-Moreno, Santiago; Chiu, April; Orazi, Attilio; Zu, Youli; Bhagat, Govind; Richards, Kristy L; Hsi, Eric D; Choi, William W L; van Krieken, J Han; Huh, Jooryung; Ponzoni, Maurilio; Ferreri, Andrés J M; Parsons, Ben M; Møller, Michael B; Wang, Sa A; Miranda, Roberto N; Piris, Miguel A; Winter, Jane N; Medeiros, L Jeffrey; Li, Yong; Young, Ken H.
Clin Cancer Res
; 22(14): 3593-605, 2016 07 15.
Artigo em Inglês | MEDLINE | ID: mdl-26927665
Untangling the Web of Lymphoma Somatic Mutations.
Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma.
Double-Hit Large B Cell Lymphoma.
P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphoma.
Multiplex polymerase chain reaction-based prognostic models in diffuse large B-cell lymphoma patients treated with R-CHOP.
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Cell-of-origin classification by gene expression and MYC-rearrangements in diffuse large B-cell lymphoma of children and adolescents.
TP53 and outcome in DLBCL: not only the coding region.
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.